SB0285 Engrossed

1 AN ACT concerning criminal law.

## 2 Be it enacted by the People of the State of Illinois, 3 represented in the General Assembly:

4 Section 5. The Illinois Controlled Substances Act is 5 amended by changing Sections 316 and 317 and by adding Section 6 316.1 as follows:

7 (720 ILCS 570/316)

8 Sec. 316. Prescription Monitoring Program.

9 (a) The Department must provide for a Prescription 10 Monitoring Program for Schedule II, III, IV, and V controlled 11 substances that includes the following components and 12 requirements:

13 (1) The dispenser must transmit to the central
14 repository, in a form and manner specified by the
15 Department, the following information:

16

17

(A) The recipient's name and address.

(B) The recipient's date of birth and gender.

18 (C) The national drug code number of the19 controlled substance dispensed.

20 (D) <u>(Blank).</u> The date the controlled substance is 21 dispensed.

(E) The quantity of the controlled substancedispensed and days supply.

SB0285 Engrossed

## - 2 - LRB103 25015 RLC 51349 b

(F) The dispenser's United States Drug Enforcement
 Administration registration number.

3 (G) The prescriber's United States Drug
 4 Enforcement Administration registration number.

5 (H) The dates the controlled substance 6 prescription is filled.

7 (I) The payment type used to purchase the
8 controlled substance (i.e. Medicaid, cash, third party
9 insurance).

(J) The patient location code (i.e. home, nursing
home, outpatient, etc.) for the controlled substances
other than those filled at a retail pharmacy.

13 (K) Any additional information that may be
14 required by the department by administrative rule,
15 including but not limited to information required for
16 compliance with the criteria for electronic reporting
17 of the American Society for Automation and Pharmacy or
18 its successor.

19 (2) The information required to be transmitted under
20 this Section must be transmitted not later than the end of
21 the business day on which a controlled substance is
22 dispensed, or at such other time as may be required by the
23 Department by administrative rule.

24 (3) A dispenser must transmit <u>electronically, as</u>
 25 <u>provided by Department rule,</u> the information required <u>to</u>
 26 <u>be transmitted</u> under this Section. <del>by:</del>

1 (A)an electronic device compatible 2 receiving device of the central repository; 3 (B) a computer diskette; 4 (C) a magnetic tape; or 5 a pharmacy universal claim form <del>(D)</del> 6 Inventory Control form. 7 (3.5) The requirements of paragraphs (1), (2), and (3) of this subsection also apply to opioid treatment programs 8 9 that are licensed or certified by the Department of Human 10 Services' Division of Substance Use Prevention and 11 Recovery and authorized by the federal are Druq 12 Enforcement Administration to prescribe Schedule II, III, IV, or V controlled substances for the treatment of opioid 13 14 use disorders. Opioid treatment programs shall attempt to 15 obtain written patient consent, shall document attempts to 16 obtain the written consent, and shall not transmit 17 information without patient consent. Documentation obtained under this paragraph shall not be utilized for 18 19 law enforcement purposes, as proscribed under 42 CFR 2, as 20 amended by 42 U.S.C. 290dd-2. Treatment of a patient shall 21 not be conditioned upon his or her written consent.

(4) The Department may impose a civil fine of up to
\$100 per day for willful failure to report controlled
substance dispensing to the Prescription Monitoring
Program. The fine shall be calculated on no more than the
number of days from the time the report was required to be

- 4 -SB0285 Engrossed LRB103 25015 RLC 51349 b

1 2 made until the time the problem was resolved, and shall be payable to the Prescription Monitoring Program.

3 (a-5) Notwithstanding subsection (a), a licensed veterinarian is exempt from the reporting requirements of this 4 5 Section. If a person who is presenting an animal for treatment fraudulently obtaining any controlled 6 is suspected of substance or prescription for a controlled substance, the 7 8 licensed veterinarian shall report that information to the 9 local law enforcement agency.

10 (b) The Department, by rule, may include in the 11 Prescription Monitoring Program certain other select drugs 12 that are not included in Schedule II, III, IV, or V. The 13 Prescription Monitoring Program does not apply to controlled 14 substance prescriptions as exempted under Section 313.

15 (c) The collection of data on select drugs and scheduled 16 substances by the Prescription Monitoring Program may be used 17 as a tool for addressing oversight requirements of long-term care institutions as set forth by Public Act 18 96-1372. Long-term care pharmacies shall transmit patient medication 19 20 profiles to the Prescription Monitoring Program monthly or 21 more frequently as established by administrative rule.

22 The Department of Human Services shall appoint a (d) 23 full-time Clinical Director of the Prescription Monitoring 24 Program.

It is the <u>responsibility of any new, ceased,</u>

or

- 25
- 26
- (e) (Blank).

(f)

SB0285 Engrossed - 5 - LRB103 25015 RLC 51349 b

unconnected healthcare facility and its selected Electronic 1 2 Health Records System or Pharmacy Management System to make 3 contact with and ensure integration with the Prescription 4 Monitoring Program. As soon as practicable after the effective date of this amendatory Act of the 103rd General Assembly, the 5 Department shall adopt rules requiring Electronic Health 6 7 Records Systems and Pharmacy Management Systems to interface, by January 1, 2024, with the Prescription Monitoring Program 8 9 to ensure that providers have access to specific patient records during the treatment of their patients. The Department 10 11 shall identify actions to be taken if a prescriber's 12 Electronic Health Records System and Pharmacy Management Systems does not effectively interface with the Prescription 13 Monitoring Program once the Prescription Monitoring Program is 14 aware of the non-integrated connection. Within one year of 15 16 January 1, 2018 (the effective date of Public Act 100 564), 17 the Department shall adopt rules requiring all Electronic Health Records Systems to interface with the Prescription 18 19 Monitoring Program application program on or before January 1, 20 2021 to ensure that all providers have access to specific 21 patient records during the treatment of their patients. These 22 rules shall also address the electronic integration of 23 pharmacy records with the Prescription Monitoring Program to allow for faster transmission of the information required 24 25 under this Section. The Department shall establish actions to 26 be taken if a prescriber's Electronic Health Records

SB0285 Engrossed - 6 - LRB103 25015 RLC 51349 b

## does not effectively interface with the Prescription Monitoring Program within the required timeline.

3 (g) The Department, in consultation with the Prescription Monitoring Program Advisory Committee, shall adopt rules 4 5 allowing licensed prescribers or pharmacists who have 6 registered to access the Prescription Monitoring Program to authorize a licensed or non-licensed designee employed in that 7 licensed prescriber's office or a licensed designee in a 8 9 licensed pharmacist's pharmacy who has received training in 10 the federal Health Insurance Portability and Accountability 11 Act and 42 CFR 2 to consult the Prescription Monitoring 12 Program on their behalf. The rules shall include reasonable parameters concerning a practitioner's authority to authorize 13 14 a designee, and the eligibility of a person to be selected as a designee. In this subsection (g), "pharmacist" shall include a 15 16 clinical pharmacist employed by and designated by a Medicaid 17 Managed Care Organization providing services under Article V of the Illinois Public Aid Code under a contract with the 18 Department of Healthcare and Family Services for the sole 19 20 purpose of clinical review of services provided to persons covered by the entity under the contract to determine 21 22 compliance with subsections (a) and (b) of Section 314.5 of 23 this Act. A managed care entity pharmacist shall notify prescribers of review activities. 24

25 (Source: P.A. 101-81, eff. 7-12-19; 101-414, eff. 8-16-19;
26 102-527, eff. 8-20-21; 102-813, eff. 5-13-22.)

| 1  | (720 ILCS 570/316.1 new)                                      |
|----|---|
| 2  | Sec. 316.1. Access to the integration of pharmacy records     |
| 3  | with the Prescription Monitoring Program.                     |
| 4  | (a) Subject to the requirements and limitations set out in    |
| 5  | this Section and in administrative rule, the Department shall |
| 6  | not require, either expressly or effectively, Electronic      |
| 7  | Health Records Systems, pharmacies, or other providers to     |
| 8  | utilize a particular entity or system for access to the       |
| 9  | integration of pharmacy records with the Prescription         |
| 10 | Monitoring Program.   |
| 11 | (1) Any entity or system for integration (transmitting        |
| 12 | the data maintained by the Prescription Monitoring            |
| 13 | Program) into an Electronic Health Records System,            |
| 14 | Certified Health IT Module, Pharmacy Dispensing System, or    |
| 15 | Pharmacy Management System must meet applicable               |
| 16 | requirements outlined in administrative rule, including,      |
| 17 | but not limited to, the following:                            |
| 18 | (A) enter into a data sharing agreement with the              |
| 19 | Department of Human Services, Prescription Monitoring         |
| 20 | Program;  |
| 21 | (B) all security requirements noted within this               |
| 22 | Section, administrative rule, and all other applicable        |
| 23 | State and federal security and privacy requirements;          |
| 24 | (C) the Prescription Monitoring Program shall have            |
| 25 | administrative control over the approval of each site         |

SB0285 Engrossed - 8 - LRB103 25015 RLC 51349 b

| and individual integration point and the Prescription  |
|--|
| Monitoring Program shall have the ability to disable   |
| individual integration points, at no additional cost   |
| to the State;  |
| (D) interstate data sharing shall be completed   |
| with written authorization from the Prescription   |
| Monitoring Program;  |
| (E) data available from the Prescription   |
| Monitoring Program shall not be stored, cached, or   |
| sold and the State may inspect and review an entity or   |
| system for integration to assure and confirm the same,   |
| subject to a reasonable non-disclosure agreement, as   |
| permitted by State law, to protect the entity's or   |
| system's trade secrets or other proprietary  |
| information;   |
|  |
| (F) analysis of data shall only be allowed with  |
| (F) analysis of data shall only be allowed with express written permission from the Prescription   |
|  |
| express written permission from the Prescription   |
| express written permission from the Prescription   |
| express written permission from the Prescription<br>Monitoring Program; and<br>(G) access to audit data, shall be available in   |
| express written permission from the Prescription<br><u>Monitoring Program; and</u><br><u>(G) access to audit data, shall be available in</u><br><u>hourly to real-time increments at no cost to the</u>  |
| express written permission from the Prescription<br><u>Monitoring Program; and</u><br><u>(G) access to audit data, shall be available in</u><br><u>hourly to real-time increments at no cost to the</u><br><u>State.</u>   |
| <pre>express written permission from the Prescription<br/>Monitoring Program; and<br/>(G) access to audit data, shall be available in<br/>hourly to real-time increments at no cost to the<br/>State.<br/>(2) Electronic Health Record Systems, Certified Health</pre>   |
| <pre>express written permission from the Prescription<br/>Monitoring Program; and<br/>(G) access to audit data, shall be available in<br/>hourly to real-time increments at no cost to the<br/>State.<br/>(2) Electronic Health Record Systems, Certified Health<br/>IT Modules, Pharmacy Management Systems, and Pharmacy</pre> |
|  |

following:

1

| _  |   |
|----|---|
| 2  | (A) provide their customers (healthcare entity,         |
| 3  | pharmacy, provider, prescriber, dispenser, etc.) the    |
| 4  | choice of approved integration vendor, meeting the      |
| 5  | requirements of this Section and administrative rule,   |
| 6  | or direct connect to the Illinois Prescription          |
| 7  | Monitoring Program;                                     |
| 8  | (B) provide their customers with access to the          |
| 9  | data provided by the customer's chosen integration      |
| 10 | vendor as allowed under State and federal statute; and  |
| 11 | (C) follow all State and federal security and           |
| 12 | privacy standards.                                      |
| 13 | (3) Customers required to integrate under State or      |
| 14 | federal law must meet the requirements outlined in      |
| 15 | administrative rule, including, but not limited to, the |
| 16 | following:  |
| 17 | (A) the customer retains the choice of which            |
| 18 | integration vendor or direct connect is utilized to     |
| 19 | connect to the Illinois Prescription Monitoring         |
| 20 | Program; and  |
| 21 | (B) customers seeking to contract with a new            |
| 22 | integration vendor, shall enter into a memorandum of    |
| 23 | understanding with the Prescription Monitoring          |
| 24 | Program.  |
| 25 | (b) The Illinois Prescription Monitoring Program may    |
| 26 | exercise the power, by rule, to require Memoranda of    |

|    | SB0285 Engrossed - 10 - LRB103 25015 RLC 51349 b               |
|----|--|
| 1  | Understanding with all customers. The general contents of the  |
| 2  | memorandum of understanding shall be set out in rule and shall |
| 3  | include, but not be limited to:                                |
| 4  | (1) the acknowledgment and choice of the customer of           |
| 5  | the method of integration with the Prescription Monitoring     |
| 6  | Program and  |
| 7  | (2) the data use and other requirements on the                 |
| 8  | customer in accessing and using the Prescription               |
| 9  | Monitoring Program.  |
| 10 | <u>A fee cannot be levied as part of a memorandum of</u>       |
| 11 | understanding required by the Department under this Section.   |
| 12 | (c) Non-compliance by the Integration Vendor, Electronic       |
| 13 | Health Record System, Certified Health IT Module, Pharmacy     |
| 14 | Management System or Pharmacy Dispensing System, customer, or  |
| 15 | any parties required to comply with this Section may result in |
| 16 | the party being prohibited from serving as entity or system    |
| 17 | for integration with the Prescription Monitoring Program,      |
| 18 | termination of contracts, agreements, or other business        |
| 19 | relationships. The Department shall institute appropriate cure |
| 20 | notices, as necessary to remedy non-compliance.                |
|    |  |
| 21 | (720 ILCS 570/317)   |
| 22 | Sec. 317. Central repository for collection of                 |
| 23 | information.   |
| 24 | (a) The Department must designate a central repository for     |
| 25 | the collection of information transmitted under Section 316    |

SB0285 Engrossed - 11 - LRB103 25015 RLC 51349 b

1 and former Section 321.

(b) The central repository must do the following: 2 (1) Create a database for information required to be 3 transmitted under Section 316 in the form required under 4 5 rules adopted by the Department, including search capability for the following: 6 7 (A) A recipient's name and address. (B) A recipient's date of birth and gender. 8 9 (C) The national drug code number of a controlled 10 substance dispensed. 11 (D) (Blank). The dates a controlled substance is 12 dispensed. 13 (E) The quantities and days supply of a controlled 14 substance dispensed. 15 (F) A dispenser's Administration registration 16 number. 17 (G) A prescriber's Administration registration number. 18 19 (H) The dates the controlled substance 20 prescription is filled. The payment type used to purchase the 21 (I) 22 controlled substance (i.e. Medicaid, cash, third party 23 insurance). (J) The patient location code (i.e. home, nursing 24 home, outpatient, etc.) for controlled substance 25 26 prescriptions other than those filled at a retail

SB0285 Engrossed - 12 - LRB103 25015 RLC 51349 b

1 pharmacy.

2 (2) Provide the Department with a database maintained 3 by the central repository. The Department of Financial and 4 Professional Regulation must provide the Department with 5 electronic access to the license information of a 6 prescriber or dispenser.

7 (3) Secure the information collected by the central
8 repository and the database maintained by the central
9 repository against access by unauthorized persons.

10 All prescribers shall designate one or more medical 11 specialties or fields of medical care and treatment for which 12 the prescriber prescribes controlled substances when 13 registering with the Prescription Monitoring Program.

14 No fee shall be charged for access by a prescriber or 15 dispenser.

16 (Source: P.A. 99-480, eff. 9-9-15.)

Section 99. Effective date. This Act takes effect upon becoming law, except that Section 316.1 takes effect July 1, 2024.